Article Details
Retrieved on: 2025-02-26 21:40:37
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Reports Q4 revenue $18.75M, consensus $17.09M. “Theravance Biopharma (TBPH) ended 2024 on a high note, having collaborated closely with Viatris .
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here